Genetics Report

**Patient details:**

Sample details:

Clinical Summary: CML on imatinib for 18 months. For *BCR-ABL1* monitoring by RT-qPCR.

BCR-ABL1 quantitative PCR (RT-qPCR) monitoring report (transcript type = e13a2/e14a2)

Treatment response	*BCR-ABL1:ABL1* % ratio on IS	MR level	Date next sample due
Warning	0.1910	MR^2	April 2017

Please note that this result could signify a resistance to treatment that may be due to an acquired mutation in the *ABL1* kinase domain (AKD) of the *BCR-ABL1* fusion gene and therefore AKD mutation testing is recommended. Please notify the laboratory if AKD testing is required on the current sample.

Level of BCR-ABL1 normalised to ABL1 on the International Scale (IS)

Reported by: Authorised by:

Laboratory Number (Sample Type)	Date received	Copies of *BCR-ABL1*	Copies of *ABL1*	*BCR-ABL1: ABL1* ratio (IS)	*BCR-ABL1: ABL1* ratio on IS (%)	Sensitivity of detection (1/*ABL1*)	Molecular Response (MR)
	27/01/2016	478,000	726,000	0.922	92.20	0.000001	#NA
	18/04/2016	7,900	78,000	0.142	14.17	0.000013	#NA
	09/05/2016	1,900	61,000	0.044	4.38	0.000017	MR^1
	21/07/2016	240	53,000	0.006	0.64	0.000019	MR^2
	21/10/2016	140	62,000	0.003	0.32	0.000016	MR^2
	19/01/2017	110	84,000	0.002	0.19	0.000012	MR^2